Altered gene expression in rat mesenteric tissue following in vivo exposure to a phosphodiesterase 4 inhibitor

Toxicology and Applied Pharmacology

Volumn 218, Issue 1, 2007, Pages 52-63

  Daguès, Nicolas ^a   Pawlowski, Valérie ^a   Guigon, Ghislaine ^a   Ledieu, David ^a   Sobry, Cécile ^a   Hanton, Gilles ^a   Freslon, Jean Louis ^b   Chevalier, Stephan ^a  

^a PFIZER INC   (United States)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Drug induced vascular injury; Gene expression; Mesentery; Microarray; PDE4 inhibitor

Indexed keywords

CI 1044; CYTOKINE; FIBRINOGEN; GLUCOSE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CONTROLLED STUDY; DISEASE MARKER; EXPOSURE; EXTRACELLULAR MATRIX; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCOSE METABOLISM; IN VIVO STUDY; INFLAMMATION; LIPID METABOLISM; MALE; MESENTERY; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NECROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; UPREGULATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; AZEPINES; CLUSTER ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INFLAMMATION; INTERLEUKINS; MALE; MESENTERIC ARTERIES; MESENTERY; NIACINAMIDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 33845875425     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.10.018     Document Type: Article

References (41)

1. Albassam M.A., Smith G.S., and Macallum G.E. Arteriopathy induced by an adenosine agonist-antihypertensive in monkeys. Toxicol. Pathol. 26 3 (1998) 375-380
2. Albassam M.A., Metz A.L., Gragtmans N.J., King L.M., Macallum G.E., Hallak H., and McGuire E.J. Coronary arteriopathy in monkeys following administration of CI-1020, an endothelin A receptor antagonist. Toxicol. Pathol. 27 2 (1999) 156-164
3. Barnette M.S. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug Res. 53 (1999) 193-229
4. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., B 57 1 (1995) 289-300
5. Bosman F.T., and Stamenkovic I. Functional structure and composition of the extracellular matrix. J. Pathol. 200 (2003) 423-428
6. Chen X.-L., Varner S.E., Rao A.S., Grey J.Y., Thomas S., Cook C.K., Wasserman M.A., Medford R.M., Jaiswal A.K., and Kunsch C. Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. J. Biol. Chem. 278 2 (2003) 703-711
7. Dietsch G.N., DiPalma C.R., Eyre R.J., Pham T.Q., Poole K.M., Pefaur N.B., Welch W.D., Trueblood E., Kerns W.D., and Kanaly S.T. Characterisation of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol. Pathol. 34 1 (2006) 39-51
8. Enerson B.E., Lin A., Lu B., Zhao H., Lawton M.P., and Floyd E. Acute drug-induced vascular injury in beagle dogs: pathology and correlating genomic expression. Toxicol. Pathol. 34 1 (2006) 27-32
9. Esmon C.T. The impact of the inflammatory response on coagulation. Thromb. Res. 114 5-6 (2004) 321-327
10. Haq F., Mahoney M., and Koropatnick J. Signaling events for metallothionein induction. Mutat. Res. 533 1-2 (2003) 211-226
11. Jitrapakdee S., and Wallace J.C. Structure, function and regulation of pyruvate carboxylase. Biochem. J. 340 Pt. 1 (1999) 1-16
12. Joseph E.C. Arterial lesions induced by phosphodiesterase III (PDE III) inhibitors and DA1 agonists. Toxicol. Lett. 112-113 (2000) 537-546
13. Kagan H.M., and Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J. Cell. Biochem. 88 (2003) 660-672
14. Kerns W.D., Arena E., Macia R.A., Bugelski P.J., Matthews W.D., and Morgan D.G. Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat. Toxicol. Pathol. 17 1 Pt. 2 (1989) 203-213
15. Kerns W., Schwartz L., Blanchard K., Burchiel S., Essayan D., Fung E., Johnson R., Lawton M., Louden C., MacGregor J., Miller F., Nagarkatti P., Robertson D., Sistare F., Snyder P., Thomas H., Wagner B., Ward A., Zhang J., and Expert Working Group on Drug-Induced Vascular Injury. Drug-induced vascular injury-a quest for biomarkers. Toxicol. Appl. Pharmacol. 203 1 (2005) 62-87
16. Kimura H., Sawada T., Oshima S., Kozawa K., Ishioka T., and Kato M. Toxicity and roles of reactive oxygen species. Curr. Drug Targets Inflamm. Allergy 4 4 (2005) 489-495
17. Lagente V., Martin-Chouly C.A.E., Boichot E., Martins M.A., and Silva P.M.R. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem. Inst. Oswaldo Cruz 100 Suppl. 1 (2005) 131-136
18. Larson J.L., Pino M.V., Geiger L.E., and Simeone C.R. The toxicity of repeated exposures to Rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol. Toxicol. 78 (1996) 44-49
19. Livak K.G., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) Method. Methods 25 4 (2001) 402-408
20. Losco P.E., Evans E.W., Barat S.A., Blackshear P.E., Reyderman L., Fine J.S., Bober L.A., Anthes J.C., Mirro E.J., and Cuss F.M. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol. Pathol. 32 (2004) 295-308
21. Louden C., and Morgan D.G. Pathology and pathophysiology of drug-induced arterial injury in laboratory animals and its implications on the evaluation of novel chemical entities for human clinical trials. Pharmacol. Toxicol. 89 (2001) 158-170
22. Louden C., Nambi P., Branch C., Gossett K., Pullen M., Eustis S., and Solleveld H.A. Coronary arterial lesions in dogs treated with an endothelin receptor antagonist. J. Cardiovasc. Pharmacol. 31 Suppl. 1 (1998) S384-S385
23. Mecklenburg L., Heuser A., Juengling T., Kohler M., Foell R., Ockert D., Tuch K., and Bode G. Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor. Toxicol. Lett. 163 1 (2006) 54-64
24. Ohta K., and Yachie A. Development of vascular biology over the past 10 years: Heme oxygenase-1 in cardiovascular homeostasis. J. Endovascular Ther. 11 Suppl. 2 (2004) 140-150
25. Okahara K., Sun B., and Kambayashi J.-I. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1922-1926
26. Ouagued M., Martin-Chouly C.A.E., Brinchault G., Leportier-Comoy C., Depincé A., Bertrand C., Lagente V., Belleguic C., and Pruniaux M.P. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-α production in whole blood from COPD patients. Pulm. Pharmacol. Ther. 18 (2005) 49-54
27. Peterson R.L., Casciotti L., Block L., Goad M.E.P., Tong Z., Meehan J.T., Jordan R.A., Vinlove M.P., Markiewicz V.R., Weed C.A., and Dorner A.J. Mechanistic toxicogenomic analysis of WAY-144122 administration in Sprague-Dawley rats. Toxicol. Appl. Pharmacol. 196 (2004) 80-94
28. Phillips P.G., Long L., Wilkins M.R., and Morrell N.W. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodelling. Am. J. Physiol.: Lung Cell. Mol. Physiol. 288 (2005) 103-115
29. Roach P.J. Glycogen and its metabolism. Curr. Mol. Med. 2 2 (2002) 101-120
30. Robertson D.G., Reily M.D., Albassam M., and Dethloff L.A. Metabonomic assessment of vasculitis in rats. Cardiovasc. Toxicol. 1 1 (2001) 7-19
31. Slim R.M., Robertson D.G., Albassam M., Reily M.D., Robosky L., and Dethloff L.A. Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats. Toxicol. Appl. Pharmacol. 183 (2002) 108-116
32. Slim R.M., Song Y., Albassam M., and Dethloff L.A. Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxicol. Pathol. 31 (2003) 638-645
33. Striz I., and Trebichavsky I. Calprotectin-a pleiotropic molecule in acute and chronic inflammation. Physiol. Res. 53 (2004) 245-253
34. Taniyama Y., and Griendling K.K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42 6 (2003) 1075-1081
35. Tayebjee M., Lip G.Y.H., and MacFadyen R.J. Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr. Med. Chem. 12 8 (2005) 917-925
36. Topper J.N., and Gimbrone M.A. Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype. Mol. Med. Today 5 1 (1999) 40-46
37. Torphy T.J. Phosphodiesterase isozymes molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157 (1998) 351-370
38. Towle H.C., Kaytor E.N., and Shih H.M. Regulation of the expression of lipogenic enzyme genes by carbohydrate. Annu. Rev. Nutr. 17 (1997) 405-433
39. Tucker R.P. The thrombospondin type 1 repeat superfamily. Int. J. Biochem. Cell Biol. 36 6 (2004) 969-974
40. Wang X., Louden C., Yue T.L., Elisson J.A., Barone F.C., Solleveld H.A., and Feuerstein G.Z. Delayed expression of osteopontin after focal stroke in the rat. J. Neurosci. 18 6 (1998) 2075-2083
41. Zhang K.Y.J., Prabha N.I., Gillette S., and Bollag G. Phosphodiesterase-4 as a potential drug target. Expert Opin. Ther. Targets 9 6 (2005) 1283-1305